CATALYTIC ACTIVITY OF TETRAHYDROBIOPTERIN IN DIHYDROPTERIDINE REDUCTASE DEFICIENCY AND INDICATIONS FOR TREATMENT

被引:15
作者
PONZONE, A
GUARDAMAGNA, O
DIANZANI, I
PONZONE, R
FERRERO, GB
SPADA, M
COTTON, RGH
机构
[1] ROYAL CHILDRENS HOSP,MURDOCH INST,OLIVE MILLER LAB,FLEMINGTON RD,PARKVILLE,VIC 3052,AUSTRALIA
[2] UNIV TURIN,DEPT PEDIAT,I-10126 TURIN,ITALY
关键词
D O I
10.1203/00006450-199302000-00007
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
It is now widely accepted that tetrahydrobiopterin (BH4), the natural cofactor of aromatic amino acid hydroxylases, in the absence of its regenerating enzyme dihydropteridine reductase (DHPR), will function only stoichiometrically in the phenylalanine (Phe) hydroxylating system. This has limited the use of pterin cofactor in diagnosis and treatment of patients suffering from inherited DHPR deficiency, one of the most common forms of hyperphenylalaninemia caused by BH4 deficiency. This is despite the observation of a dramatic fall in serum Phe concentration after BH4 loading in such patients. In this study, quantitation of this phenomenon was obtained by comparing the kinetics of serum Phe after either a simple Phe or a combined Phe plus BH4 oral loading in patients with Phe hydroxylase or with DHPR deficiency. Only in the latter was the total body clearance of Phe enhanced up to 5 times by the cofactor administration, resulting in the molar equivalent of Phe hydroxylated/mol of BH4 ranging from at least 6 to 10, against the postulated 1. As a consequence, BH4 administration should be attempted therapeutically in DHPR-deficient patients, thus avoiding a lifelong Phe-restricted diet. Preliminary experience with such treatment is given with two cases.
引用
收藏
页码:125 / 128
页数:4
相关论文
共 23 条
[1]  
ARAI N, 1982, PEDIATRICS, V70, P426
[2]   TETRAHYDROBIOPTERIN NONRESPONSIVENESS IN DIHYDROPTERIDINE REDUCTASE DEFICIENCY IS ASSOCIATED WITH THE PRESENCE OF MUTANT PROTEIN [J].
COTTON, RGH ;
JENNINGS, I ;
BRACCO, G ;
PONZONE, A ;
GUARDAMAGNA, O .
JOURNAL OF INHERITED METABOLIC DISEASE, 1986, 9 (03) :239-243
[3]  
DANKS DM, 1975, LANCET, V2, P1043
[4]  
FERRARIS S, 1987, UNCONJUGATED PTERINS, P283
[5]  
GIBALDI M, 1975, PHARMACOKINETICS
[6]  
HOWELLS D, 1986, NEW ENGL J MED, V314, P520
[7]  
KAFMAN S, 1975, NEW ENGL J MED, V93, P785
[9]  
KAUFMAN S, 1975, LANCET, V2, P767